Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Get Free Report)’s stock price crossed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $3.87 and traded as high as $3.89. Armata Pharmaceuticals shares last traded at $3.89, with a volume of 50,548 shares trading hands.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Armata Pharmaceuticals in a research report on Tuesday, September 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $15.00.
View Our Latest Report on Armata Pharmaceuticals
Armata Pharmaceuticals Price Performance
The business’s 50 day moving average is $3.80 and its two-hundred day moving average is $6.85.
Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.32. Armata Pharmaceuticals had a negative net margin of 1,626.27% and a negative return on equity of 33.09%. The business had revenue of $3.17 million during the quarter, compared to analysts’ expectations of $0.45 million. As a group, equities analysts anticipate that Armata Pharmaceuticals, Inc. will post 0.50 EPS for the current fiscal year.
Institutional Trading of Armata Pharmaceuticals
A number of hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE bought a new position in Armata Pharmaceuticals in the second quarter valued at $73,000. Deutsche Bank AG bought a new stake in Armata Pharmaceuticals during the second quarter worth about $78,000. Nisa Investment Advisors LLC bought a new stake in Armata Pharmaceuticals during the third quarter worth about $50,000. Bank of New York Mellon Corp bought a new stake in Armata Pharmaceuticals during the second quarter worth about $193,000. Finally, Empowered Funds LLC purchased a new position in shares of Armata Pharmaceuticals in the 3rd quarter worth about $149,000. 3.57% of the stock is owned by institutional investors.
Armata Pharmaceuticals Company Profile
Armata Pharmaceuticals is a clinical-stage biotechnology company developing bacteriophage-based treatments for bacterial infections. Bacteriophages are viruses that infect and kill specific bacteria, and Armata’s approach is intended to target disease-causing bacteria, including strains that are difficult to treat with antibiotics. The company’s development programs have included AP-PA02, an inhaled phage therapy being studied for Pseudomonas aeruginosa lung infections, and AP-SA02, an intravenous therapy targeting Staphylococcus aureus infections.
Recommended Stories
- Five stocks we like better than Armata Pharmaceuticals
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
